A Phase I Dose-Finding Study to Evaluate Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

Study Identifier:
CV-HNLC-001
CT.gov Identifier:
NCT07073183
EudraCT Identifier:
202452000000
EU Trial (CTIS) Number:
2024-519651-28-00
Study Contact Information:
(210) 593-5651 or [email protected]
Will Be Recruiting

Considering participating in a START clinical trial?

Get Started

Study Summary

This is an open-label, first-in-human, dose escalation study of CV09070101 mRNA (CVHNLC) in patients with metastatic Squamous Non-Small-Cell Lung Cancer (sqNSCLC).

The study will evaluate the safety and tolerability of CVHNLC plus pembrolizumab in an Dose Escalation Part and, once the safety of this combination is established, CVHNLC plus prembrolizumab and chemotherapy (carboplatin and paclitaxel) will be evaluated in an Dose Expansion Part with the recommended dose selected from the Dose Escalation Part.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Non-Small Cell Lung Cancer
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    I
    Sex
    Female & Male
    Age
    18+ years
    Study Drug
  • Drug: Experimental: Dose escalation: CVHNLC Dose level -1
    • Read More
  • Drug: Experimental: Dose escalation: CVHNLC Dose level 1Biological: CV09070101 mRNA vaccine (CVHNLC) 100 µg
  • Drug: Experimental: Dose escalation: CVHNLC Dose level 2Biological: CV09070101 mRNA vaccine (CVHNLC) 200 µg
  • Drug: Experimental: Dose escalation: CVHNLC Dose level 3Biological: CV09070101 mRNA vaccine (CVHNLC) 400 µg
  • Drug: Experimental: Dose expansion
  • Drug: Subject have received 3-6 months of treatment with pembrolizumab either as monotherapy or in combination with ≥2 cycles of platinum-based chemotherapy as first-line treatment, with no documented disease progression and eligible for pembrolizumab maintenance therapy. CVHNLC doses between 100 µg and 400 µg will be investigated, guided by a Bayesian Logistic Regression Model. Patients will initially receive 4 weekly intramuscular injections of CVHNLC followed by 3-weekly injections plus pembrolizumab for up to 12 months or until disease progression or undue toxicity.
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Will Be Recruiting

    Requirements information
    Inclusion criteria
    • Dose Escalation Part (Metastatic 1L Maintenance sqNSCLC)
    • 1. Patients with histologically confirmed metastatic Stage IV (per American Joint Commission on Cancer (AJCC) Staging Manual, Eighth Edition) sqNSCLC not amenable for surgical or locoregional therapy.
    • 2. Patients who have received pembrolizumab for 3 months but no longer than 6 months from start of pembrolizumab treatment (at least 3 cycles with a total dose of 600 mg), either as monotherapy or in combination with at least 2 cycles of chemotherapy with carboplatin and (nab-)paclitaxel as first-line treatment with no documented disease progression and who are indicated for maintenance therapy with pembrolizumab.
    • 3. Patients able to tolerate further anti-PD-1 therapy i.e., no criteria for permanent discontinuation of pembrolizumab due to toxicity have been met during previous treatment.
    • 4. No known targetable molecular aberration.
    • 5. Patients having measurable disease according to RECIST 1.1.
    • Dose Expansion Part (Metastatic 1L sqNSCLC)
    • 1. Patients with histologically confirmed metastatic sqNSCLC (AJCC Staging Manual, Eighth Edition) not amenable for surgical or locoregional therapy and being eligible for first-line treatment with pembrolizumab and chemotherapy with carboplatin and paclitaxel. Patients should not have received any prior systemic treatment for metastatic disease. Previous (neo-)adjuvant treatment is allowed if there are at least 12 months between end of this treatment and development of metastatic disease.
    • Inclusion Criteria applying to both Parts
    • 1. Available formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from non- irradiated lesions that are not older than 6 months for retrospective assessment of antigen expression and potential other biomarker analyses (in total 15 slides of at least 5 μm thickness or equivalent amount provided as a single block).
    • 2. Recovered from all AEs related to prior therapies including anti-PD-(L)1 inhibitor treatment-related AEs to CTCAE Grade ≤ 1 or baseline (except for alopecia areata, vitiligo, chemotherapy induced polyneuropathy or endocrinopathies that are compensated by hormone replacement and Grade 2 lymphopenia).
    • 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    • 4. Age ≥ 18 years on date of signing informed consent form (ICF).
    • 5. Each patient must voluntarily sign and date an ICF approved by an Independent Ethics Committee (IEC), prior to the initiation of any, screening or trial-specific procedures.
    • 6. Life expectancy ≥ 6 months.
    • 7. Females who are post-menopausal (no menses for at least 12 months before the Screening Visit), or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
    • Females of childbearing potential must:
    • 1. Have a negative serum pregnancy test (hCG) with a sensitivity of at least 25 mIU/mL within 10 to 14 days, and within 24 hours prior to starting the trial treatment a negative urine pregnancy test if serum pregnancy test not done within 24 hours prior to starting the trial treatment.
    • 2. Agree to ongoing pregnancy testing during the trial.
    • 3. Use effective contraception at least 28 days before starting trial treatment through 30 days after the last dose of trial treatment. Effective methods of birth control include:
    • * Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:
    • * oral
    • * intravaginal
    • * transdermal
    • * Progestogen-only hormonal contraception associated with inhibition of ovulation:
    • * oral
    • * injectable
    • * implantable
    • * Intrauterine device
    • * Intrauterine hormone-releasing system
    • * Bilateral tubal ligation
    • * Vasectomized partner + barrier method
    • 8. Male patients, even if surgically sterilized (e.g., status post vasectomy), must:
    • 1. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal (coitus interruptus), spermicides only and lactational amenorrhea method are not acceptable methods of contraception.
    • 2. Agree to practice effective barrier contraception (condom) during the entire trial treatment period and through to 3 months after the last dose of trial treatment if their partner is of childbearing potential, even if they have had a successful vasectomy.
    • 9. Male patients must refrain from sperm donation and female patients of childbearing potential must refrain from egg donation during the entire trial treatment period and through to 3 months after the last dose of trial treatment.
    • 10. Able to understand the requirements of the trial and comply with the trial protocol procedures.
    • Patients with histologically confirmed metastatic stage IV sqNSCLC will be eligible
    Exclusion criteria
    • 1. Disease progression on or within 12 months after the last dose of (neo-)adjuvant anti PD-(L)1 treatment before start of first-line treatment.
    • 2. Prior radiotherapy within 2 weeks before start of trial treatment.
    • 3. History of other malignancies unless the patient has undergone potentially curative treatment without evidence of recurrence within the last 3 years. Exception is BCC or carcinoma in situ of any site that has been adequately treated (with the exception of systemic therapy).
    • 4. Previous anaphylactic or severe allergic reaction to LNP-formulated drug or (mRNA) vaccine (or known allergy to any other component of CVHNLC).
    • 5. Allergy to aminoglycoside or beta-lactam antibiotics.
    • 6. History of previous permanent discontinuation of anti-PD-(L)1 therapy due to toxicity or any other contraindications to treatment with pembrolizumab, including severe hypersensitivity to anti-PD-1 checkpoint inhibitors, its active substance, or one of its excipients.
    • 7. Abnormal (≥ Grade 2 NCI-CTCAE v5.0) laboratory values as follows:
    • 1. Hemoglobin < 10 g/dL (6.2 mmol/L).
    • 2. White blood cell (WBC) count decrease < 2.5 ×109/L.
    • 3. Absolute neutrophil count (ANC) decrease < 1.5 ×109/L.
    • 4. Absolute lymphocyte count (ALC) decrease < 0.5 ×109/L.
    • 5. Platelet count decrease < 75 ×109/L.
    • 6. Bilirubin > 1.5 × upper limit of normal (ULN according to the performing lab's reference range), except for patients with Gilbert's syndrome.
    • 7. Alanine aminotransferase (ALT) > 3 × ULN (or ≤ 5 in patients with liver metastasis).
    • 8. Aspartate aminotransferase (AST) > 3 × ULN. (or ≤ 5 in patients with liver metastasis).
    • 9. Serum creatinine increased > 1.5 × ULN or creatinine clearance < 50 mL/min.
    • 10. Serum Albumin < 30 g/L.
    • 8. Received steroid treatment with doses exceeding 10 mg prednisolone or equivalent per day within 3 days prior to enrollment and/or requiring continued treatment with steroid doses above 10 mg/day prednisolone or equivalent or any other systemic immunosuppressive treatment within 28 days prior to enrollment or requiring chronic immunosuppression with such treatment. Inhalation steroids or topical steroids are allowed.
    • 9. Active infections requiring antibiotic treatment, associated with fever > 38°C or expected to potentially result in severe disease.
    • 10. Patients with known active hepatitis B (presence of HBsAg) or hepatitis C (presence of Hep C Ab) at screening or within 3 months prior to first trial treatment. In case of positive Hep C Ab, subjects may be enrolled in case of a negative confirmatory hepatitis C virus (HCV) RNA polymerase chain reaction (PCR) test.
    • 11. Patients with seropositivity of human immunodeficiency virus (HIV).
    • 12. Active autoimmune diseases (except for vitiligo or autoimmune thyroid disease that is stable under treatment), requiring treatment with steroids, disease modifying agents or immunosuppressants.
    • 13. Brain metastases or evidence of leptomeningeal tumor spread (with exception of stable brain metastases controlled by radiotherapy or other treatment without need for steroid treatment).
    • 14. Immunosuppression other than related to prior treatment of malignancy (i.e., platinum-based chemotherapy).
    • 15. Previous hematopoietic stem cell or solid organ transplantation.
    • 16. Any condition that in the judgment of the Investigator is likely to prevent compliance with trial procedures.
    • 17. Previous immune-mediated pneumonitis, myocarditis, immune-mediated hepatitis, encephalitis or Guillain-Barre syndrome of any grade, any occurrence of a ≥ Grade 3 immune-mediated AE during previous treatment with pembrolizumab (with the exception of endocrinopathies stable under hormone replacement).
    • 18. Patients with impaired coagulation or any bleeding disorder in whom an intramuscular injection or blood draw is contraindicated.
    • 19. History of myocarditis or pericarditis within the last 6 months or history of myocarditis or pericarditis following mRNA COVID-19 vaccination.
    • 20. Previous prophylactic mRNA vaccination (e.g., SARS-CoV2) or live attenuated vaccination within 30 days prior to first administration of CVHNLC treatment and other vaccines within 2 weeks prior to first administration of CVHNLC treatment.
    • 21. Previous anticancer vaccine administrations.
    • 22. Serious illness or condition, which according to the Investigator poses an undue risk for the patient when participating in the trial, including, but not limited to, any of the following:
    • 1. Clinically significant cardiovascular disease (myocardial infarction or stroke within the last 6 months, uncontrolled angina within last 3 months, diagnosed or suspected clinically significant ventricular arrhythmias, ejection fraction < 45%, cerebrovascular event within last 6 months, uncontrolled hypertension [blood pressure > 160 mmHg systolic and 100 mmHg diastolic despite] medication).
    • 2. New York Heart Association (NYHA) Class III to IV congestive heart failure.
    • 3. Symptomatic peripheral vascular disease.
    • 4. Severe pulmonary disease (e.g., severe chronic obstructive pulmonary disease or pulmonary fibrosis), active or history of non-infectious pneumonitis or interstitial lung disease requiring steroids.
    • 23. Uncontrolled diabetes (repeated episodes of severe hypo- or hyperglycemia requiring hospitalization).
    • 24. Severe mental retardation/impairment, psychiatric conditions or substance abuse resulting in inability to understand informed consent or affecting patient's cooperation in the trial.
    • 25. Pregnant or breastfeeding patients.
    • 26. Concurrent or prior (within 30 days or at least 5 half-lives of investigational product, whatever is longer prior to trial enrollment) participation in another investigational clinical trial studying an investigational product or treatment regimen.
    • 27. Patients with any contraindications to the SOC/AxMP as detailed in the approved product label or SmPC/USPI.

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START Madrid, Spain (CIOCC)
    Madrid, Spain, 28050
    Investigator
    Irene Moreno
    Status
    Recruitment on Hold
    Condition(s) Treated at Site
    Non-Small Cell Lung Cancer